MoonLake Immunotherapeutics

NasdaqCM MLTX

MoonLake Immunotherapeutics Price to Earnings Ratio (P/E) on December 30, 2024: -41.40

MoonLake Immunotherapeutics Price to Earnings Ratio (P/E) is -41.40 on December 30, 2024, a 55.16% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

MoonLake Immunotherapeutics 52-week high Price to Earnings Ratio (P/E) is -35.82 on October 24, 2024, which is 13.47% above the current Price to Earnings Ratio (P/E).
MoonLake Immunotherapeutics 52-week low Price to Earnings Ratio (P/E) is -102.26 on February 12, 2024, which is -147.01% below the current Price to Earnings Ratio (P/E).
MoonLake Immunotherapeutics average Price to Earnings Ratio (P/E) for the last 52 weeks is -59.95.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: MLTX

MoonLake Immunotherapeutics

CEO	Dr. Jorge Santos da Silva
IPO Date	Oct. 20, 2020
Location	Switzerland
Headquarters	Dorfstrasse 29
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Key trends

Past 5 years